GENERATE BIOMEDICINES INC (GENB)
Health Care · Biotechnology / AI-Drug Discovery · NASDAQ
Generate Biomedicines is an AI-powered biotechnology company focused on creating a new generation of programmable protein therapeutics.
What GENERATE BIOMEDICINES INC does
Generate Biomedicines is a biotechnology company that utilizes a proprietary artificial intelligence platform, The Generate Platform, to discover and develop novel protein therapeutics. The company focuses on creating programmable protein medicines by integrating machine learning with high-throughput biological experimentation. Its business model includes internal drug development and potential collaboration and licensing agreements.
Themes: AI drug discovery, Protein therapeutics, Generative AI, Computational biology
Fundamentals
- Price$13.99 as of 2026-10-08 close
- Market cap$1.8B as of 2026-07-29 (share count; price 2026-10-08)
- P/En/a earnings data not available
- Debt / equity0.01 as of 2026-09-03
- Revenue growth (YoY)-37.7% as of 2026-09-03
- Beta1.21 as of 2026-09-03
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How GENERATE BIOMEDICINES INC looks technically
GENERATE BIOMEDICINES INC (GENB): a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 2 trading days ago.
Trend
8
| Distance from the 200-day | not enough price history yet — needs 200 trading sessions | n/a |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $15.51 | $15.51 |
| 200-day moving average | not enough price history yet — needs 200 trading sessions | n/a |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 17.97. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | not enough price history yet — needs 200 trading sessions | n/a |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend) | 22.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30) | 40.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($13.08 to $17.97) — its "stochastic" reading is 19 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 18.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 11 sessions |
Range
7
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
|---|---|---|
| Since a 55-day breakout | it made a new 55-day high about 32 trading days ago | 32 sessions |
| All-time high | its highest closing price on record is $22.67 (set on 2026-08-25) | $22.67 |
| Given back of the 52-week move | not available for this company yet | n/a |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $11.00 (set on 2026-03-04) | $11.00 |
| Above the all-time low | it is 27.2% above its all-time low | +27.2% |
Volatility
4
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 67th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.9695 between its high and its low — about 6.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.9695 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $12.86 and $17.99 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $12.86 – $15.42 – $17.99 |
| Typical daily range (% of price) | its price moves about 6.9% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.9% |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.85× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bullish engulfing | today it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | today |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.5% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.5% |
|---|---|---|
| Gap filled | a 2.3% gap up opened on 2026-09-17 has been "filled" 10 sessions ago — price traded back through the level the gap left behind, and it took 5 sessions to close | 10 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 13.1 percentage points (the stock lost 12.0% while the market gained 1.0%) | -13.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 15.7 percentage points (the stock lost 11.8% while the market gained 3.8%) | -15.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 1.8 percentage points (the stock gained 15.6% while the market gained 17.5%) | -1.8% |
| vs market, 12 months | not available for this company yet | n/a |
Signal agreement
2
| Bullish technical signals | 1 of the 7 technical signals we can compute for it is currently in a bullish state: near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 1 of 7 |
|---|---|---|
| Bearish technical signals | 4 of the 7 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 7 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 20% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 4.0% of the share price. | -20.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 6% below the average price paid since 2026-02-27, so the typical buyer over that stretch is under water. That average is $14.91 — a volume-weighted average of daily closes over 145 sessions, not a true tick-by-tick VWAP. | -6.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 13% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $16.12 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | -13.2% |
Head and shoulders, bearish — broke down · entry $16.79 · 68 sessions in
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $17.97.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 8 trading days, since 2026-09-29.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Broke down to a new 20-day low · Printed a bullish engulfing pair · Most volatile (6%+ typical daily range) · At the bottom of its 14-day range (stochastic below 20) · Under water since its last earnings report (below the anchored VWAP) · Trading below the Ichimoku cloud | Learn: adx · rsi · breakout
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.33 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$27.00 range $22.00 – $30.00
Analyst estimates, as of 2026-10-09. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for GENB
- Consensus EPS estimate-$0.545 next reporting period, as of 2026-10-09
- Estimate change, 30 days$0.00 from -$0.545, on 2026-09-04, 35-day window
- Readings revised upward13% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on the success of its AI-driven drug discovery platform and the ability of preclinical studies to predict clinical trial outcomes.","Significant history of losses and the need for substantial additional capital to fund research, development, and operations.","Uncertainties regarding regulatory approvals, market acceptance of AI-discovered therapies, and protection of intellectual property."]
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 1 sell ($16002) — 1 selling insider
- Last 180 days · read to 2026-10-040 buys · 1 sell ($16002) — 1 selling insider
Cluster buying: 4 different insiders reported open-market purchases (SEC code P) of GENB within a 30-day window between 2026-03-02 and 2026-03-04. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-01. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about GENB's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding GENB as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 8,732,432
- Reported value $147,316,132
reported quarterly holdings change (2026-03-31 → 2026-06-30): 3 new, 2 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about GENB's institutional holders → See what each manager we track holds →
Short interest (FINRA)
GENB had 7,180,013 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
GENB had 5.59% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.24 days to cover at the same settlement.
- Reported short interest (shares) 7,180,013
- Short interest (% of shares outstanding) 5.59%
- Prior settlement (shares) 7,456,033
- Reported change -3.7%
- Days to cover (reported) 7.24
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Recursion Pharmaceuticals (RXRX)
- Schrödinger (SDGR)
- Exscientia (EXAI)
- AbCellera Biologics (ABCL)
- Relay Therapeutics (RLAY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare GENB vs…
GENERATE BIOMEDICINES INC is found in…
Frequently asked questions
What does GENERATE BIOMEDICINES INC (GENB) do?
Generate Biomedicines is a biotechnology company that utilizes a proprietary artificial intelligence platform, The Generate Platform, to discover and develop novel protein therapeutics. The company focuses on creating programmable protein medicines by integrating machine learning with high-throughput biological experimentation. Its business model includes internal drug development and potential collaboration and licensing agreements.
What sector is GENERATE BIOMEDICINES INC (GENB) in?
GENERATE BIOMEDICINES INC (GENB) is classified in the Health Care sector. Its industry is Biotechnology / AI-Drug Discovery. It trades on NASDAQ.
Who are GENERATE BIOMEDICINES INC's (GENB) competitors?
Notable peers of GENERATE BIOMEDICINES INC (GENB) include Recursion Pharmaceuticals, Schrödinger, Exscientia, AbCellera Biologics and Relay Therapeutics. This peer set is informational only — not financial advice.
Is GENERATE BIOMEDICINES INC (GENB) overbought or oversold right now?
GENERATE BIOMEDICINES INC (GENB) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 40, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on GENB come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.